Continue reading from Medscape - registration required
Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews
-- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.
Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
Saturday, October 22, 2011
Continue reading from Medscape - registration required
Imagine waking up numb. So numb, in fact, that movement is either impossible or takes all your energy. If you are able to get out of bed, fatigue plagues every moment of the day, and the tingling in arms and legs does not subside.
Multiple sclerosis is a chronic disease which attacks the central nervous system. Those diagnosed with it can be rendered wheelchair bound. It is silent, and affects no two people quite the same way.
Erica Garrett, 40-year-old Mesquite resident, supervisor of the Virgin Valley Home Care and Hospice, and a mother of four children — Morgan, 17; Madison, 11; Beau, 4; and Kole, 2 — was diagnosed with the disease in July of 2010.
“I had cut my finger on a glass,” said Erica. “And three weeks later I noticed that the tip of my finger was going numb. I thought that it was really odd, and — at first — thought I had hit a nerve; then the three (fingers) on this side went numb. I knew something was wrong.”
Tests proved that no nerve was affected. Further tests revealed no indication of a pinched nerve in Erica’s spine as well.
“My husband is a physical therapist and I am a nurse, so we were talking,” she said. “We began to think it was a brain tumor.”
Eric Garrett’s brother, a doctor, had mentioned the possibility of MS, but Erica did not consider it an option.
Three hours after her MRI, Erica and Eric were told that she had MS.
Another resident of Mesquite, Martin Barra, was diagnosed with MS in September of 2010, but his prognosis of life is much worse than that of Erica.
He also has ALS, which is known as Lou Gehrig’s disease.
“I was the sole breadwinner,” he said. “I had two jobs, insurance. We were living well. Now I am on Social Security and food stamps.”
Barra is 45 years old, and the father of four children.
According to www.nationalmssociety.org, about 400,000 people in the U.S. have been diagnosed with MS, with about 200 new cases diagnosed each week.
MS is the result of the body’s own defenses attacking the myelin — the protective fatty covering on the nerve fibers in the central nervous system — damaging and scarring the nerves. This causes interruption in the passage of impulses to and from the brain, disrupting or distorting the communication. Little more is known of the disease, accept for the fact that most of those who get it are women between the ages of 20 to 40.
New data from a late-stage trial showed that 78 percent of patients treated with Lemtrada remained relapse-free for two years, compared with 59 percent using Rebif, an older multiple sclerosis drug sold by Germany's Merck.
Friday, October 21, 2011
One of the scientists at Biogen Idec pushing for a new kind of regenerative medicine for Multiple Sclerosis
Sha Mi, Biogen Idec’s Neurology Ace, to Join “The Genetics Institute Impact” conference
I wish I could go...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced 96-week results from a Phase II study of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS), the most common clinical form of the disease. The study showed that the significant reduction in disease activity as measured by the total number of active brain lesions and relapses, previously reported for 24 weeks, was maintained through 96 weeks. The data is being presented at ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis), the world's largest annual international conference devoted to basic and clinical research in multiple sclerosis.
People with RRMS suffer from relapses and disabling symptoms caused by damage to the central nervous system (the brain, spinal cord and optic nerves) which can significantly affect their quality of life. Symptoms are unpredictable and vary between patients. Most people experience their first symptoms between the ages of 20 and 40.
Results from the trial showed that during the 24-96 week treatment period, no patient who received a dose of 600mg ocrelizumab developed a new or enlarging brain lesion (as measured by MRI). The annualized relapse rate (ARR), the rate of clinical attacks or flare-ups per patient-year, was less than 0.2 attacks per patient per year across the 96-week period. The data also showed that, of the patients who completed the study, two-thirds of the patients in the 600mg group were free of any disease activity (as measured by MRI, relapses or neurological progression) over the 96-week treatment period.